Prinolid 11,25 11,25 mg Injection
PDF Leaflet Revision Date: 24 January 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Palliative treatment of advanced prostatic cancer, endometriosis, uterine fibroids, and adjuvant therapy in breast cancer.
Dosage (summary)
11.25 mg subcutaneous or intramuscular injection every 3 months.
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- QT prolonging medications
- Anti-androgens
Contraindications
- Hypersensitivity to leuprolide acetate
- Pregnancy
- Breastfeeding
- Undiagnosed vaginal bleeding
Common side effects
- Hot flushes
- Mood swings
- Depression
- Vaginal dryness
- Injection site reactions
Counselling Points
- Use non-hormonal contraception
- Monitor blood glucose levels
- Report any severe mood changes
Serious warnings
- Risk of diabetes and cardiovascular disease
- Potential for seizures
- Bone density loss
Important Disclaimer
The Prinolid 11,25 11,25 mg Injection professional information leaflet below is the property of Eurolab and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
